How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

799 results for

Galantamine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Optimal dosing of galantamine in patients with mild or moderate Alzheimer's disease: post Hoc analysis of a randomized, double-blind, placebo-controlled trial. (PubMed)

Optimal dosing of galantamine in patients with mild or moderate Alzheimer's disease: post Hoc analysis of a randomized, double-blind, placebo-controlled trial. Galantamine (hydrobromide), a reversible acetylcholinesterase inhibitor and allosteric nicotinic receptor modulator, slows cognitive and functional decline in mild to moderate dementia of the Alzheimer's type. Although several drugs are indicated for mild to moderate Alzheimer's disease (AD), no published study has separately analysed (...) mild and moderate AD subgroups to assess the effect of dosage.To compare the efficacy and safety of galantamine 16 and 24 mg/day in patient subgroups with mild or moderate AD.This post hoc analysis (n = 838) of a 5-month, randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of galantamine 16 and 24 mg/day in a subgroup of patients with mild AD (Mini-Mental State Examination [MMSE] >18) and a subgroup with moderate AD (MMSE 10-18). Efficacy outcomes included

2009 Drugs & Aging

162. Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer's disease: systematic review of the 'real-world' evidence. (PubMed)

Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer's disease: systematic review of the 'real-world' evidence. The purpose of this systematic review was to compare the safety and tolerability of the cholinesterase inhibitors (ChEIs) donepezil, rivastigmine and galantamine for treating mild to moderate Alzheimer's disease (AD) patients in routine clinical practice.Electronic databases (Cochrane Library, Medline, EMBASE; accessed October 2008) and manual (...) bibliographic searches were conducted to identify head-to-head non-randomised studies examining ChEIs for the treatment of AD. Data were extracted by 2 independent reviewers.Twelve head-to-head studies comparing ChEIs met the pre-specified inclusion criteria; 6 retrospective analyses and 6 prospective cohort studies. Donepezil was the most widely studied treatment and galantamine the least widely prescribed therapy. Fewer donepezil-treated subjects withdrew due to adverse events (AEs) compared

Full Text available with Trip Pro

2009 Dementia and Geriatric Cognitive Disorders

163. Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia

Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum (...) number of saved studies (100). Please remove one or more studies before adding more. Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia (CIDAR-3) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01012167 Recruitment Status

2009 Clinical Trials

164. Long-term Use of Galantamine Versus Nootropics (Memory Enhancing Drugs) in Patients With Alzheimer's Dementia Under Conditions of Daily Routine

Long-term Use of Galantamine Versus Nootropics (Memory Enhancing Drugs) in Patients With Alzheimer's Dementia Under Conditions of Daily Routine Long-term Use of Galantamine Versus Nootropics (Memory Enhancing Drugs) in Patients With Alzheimer's Dementia Under Conditions of Daily Routine - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save (...) this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Long-term Use of Galantamine Versus Nootropics (Memory Enhancing Drugs) in Patients With Alzheimer's Dementia Under Conditions of Daily Routine The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details

2009 Clinical Trials

165. Galantamine Effects on Cognitive Function in Marijuana Users

Galantamine Effects on Cognitive Function in Marijuana Users Galantamine Effects on Cognitive Function in Marijuana Users - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Galantamine Effects on Cognitive (...) Information provided by (Responsible Party): Mehmet Sofuoglu, Yale University Study Details Study Description Go to Brief Summary: To evaluate galantamine's effects on cognitive performance in marijuana users. Galantamine, an acetylcholine esterase inhibitor, is approved for treatment of Alzheimer's disease. Current marijuana users show impaired cognitive functioning, which predicts poor treatment response to behavioral treatments in this population. Whether cognitive impairment in marijuana users

2009 Clinical Trials

166. Pharmacological Management of Dementia with Lewy Bodies. (PubMed)

shown to be effective in managing the cognitive and behavioral symptoms of DLB: rivastigmine, galantamine and donepezil. Memantine is able to improve clinical global impression of change in those with mild to moderate DLB. Levodopa can treat the parkinsonism of some DLB patients, but the dose is often limited due to the fact that it can cause agitation or worsening of visual hallucinations. A recent phase 2 clinical trial showed the benefit of zonisamide when it is added as an adjunct to levodopa

Full Text available with Trip Pro

2019 Drugs & Aging

167. Leaf extracts from Dendropanax morbifera Léveille mitigate mercury-induced reduction of spatial memory, as well as cell proliferation, and neuroblast differentiation in rat dentate gyrus. (PubMed)

and differentiated neuroblasts.Dimethylmercury (5 μg/kg) and galantamine (5 mg/kg) was administered intraperitoneally and/or DML (100 mg/kg) was orally to 7-week-old rats every day for 36 days. One hour after the treatment, novel object recognition test was examined. In addition, spatial probe tests were conducted on the 6th day after 5 days of continuous training in the Morris swim maze. Thereafter, the rats were euthanized for immunohistochemical staining analysis with Ki67 and doublecortin and measurement (...) the administration of DML or galantamine significantly increased the number of crossings than did dimethylmercury treatment alone. Proliferating cells and differentiated neuroblasts, assessed by Ki67 and doublecortin immunohistochemical staining was significantly decreased in the dimethylmercury treated group versus controls. Supplementation with DML or galantamine significantly increased the number of proliferating cells and differentiated neuroblasts in the dentate gyrus. In addition, treatment

Full Text available with Trip Pro

2019 BMC Complementary and Alternative Medicine

168. Ginkgo biloba Extract (EGb761), Cholinesterase Inhibitors, and Memantine for the Treatment of Mild-to-Moderate Alzheimer's Disease: A Network Meta-Analysis. (PubMed)

inconclusive.A network meta-analysis was conducted to evaluate the therapeutic benefits and tolerability of EGb761, three ChEIs (donepezil, galantamine, and rivastigmine), and memantine in mild-to-moderate AD patients.Electronic databases were searched through 30 June 2017. We included randomized double-blinded trials with a minimum treatment duration of 22 weeks for EGb761 240 mg/day and 12 weeks for ChEIs or memantine. The study patients included AD or probable AD patients without other types of dementia (...) showed no therapeutic benefits in all study outcomes. For cognition, all ChEIs were significantly better than placebo (SMD from - 0.52 to - 0.26), and galantamine was better than rivastigmine in the oral and patch forms, EGb761, and memantine (SMD [95% confidence interval (CI)]: - 0.22 [- 0.40 to - 0.05]; - 0.26 [- 0.45 to - 0.07]; - 0.34 [- 0.56 to -  0.12]; and - 0.42 [- 0.71 to - 0.13], respectively). Compared to placebo, galantamine, the rivastigmine patch, and oral rivastigmine provided modest

2019 Drugs & Aging

169. Management of schizophrenia

of augmentation of antipsychotics with acetylcholinesterase inhibitors identified 13 double blind studies (six with donepezil, three with galantamine and four with rivastigmine,). Significant improvement was found for various aspects of memory (by an average of 28%, in three studies, in 146 participants, 95% CI 0.06 to 0.50, p=0.014) and on the trail making test part A (by 69%, in four studies, in 93 participants, 95% CI -1.14 to -0.23, p=0.003). 125 B Acetylcholinesterase inhibitors may be considered

2013 SIGN

170. 5 questions to ask when writing (and reading) about new Alzheimer’s drug research

and increasingly common disease, there are only four FDA approved medications for treating symptoms: Aricept (donepizil), Razadyne (galantamine), Namenda (memantine), Exelon (rivastigmine) and Namzaric (a combination of donepezil and memantine). None of these drugs cure or slow progression, although initially, experts and drug-makers claimed that the drugs did slow the advancement of AD. But now that the drugs have been on the market for a dozen years or more–and have been the subject of numerous post-market

2017 HealthNewsReview

173. Help Versus Hope: Acetylcholinesterase Inhibitors in Alzheimer?s Disease

levels of care that often extend beyond the capabilities of family caretakers and result in high rates of patient placement in nursing homes. Preventing and reversing the dementia seen in AD in order to increase quality of life among these patients is the goal of treatment. Nevertheless, the backbone of Alzheimer’s treatment remains acetylcholinesterase inhibitors (CIs) such as donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne). Memantine (Namenda), which is also approved (...) about the benefits of acetylcholinesterase inhibitors in the treatment of Alzheimer’s disease? Numerous studies investigating the effects of CI treatment on AD progression have yielded results that many find disappointing. One such study followed 2853 persons with Alzheimer’s disease to assess for changes in Mini-Mental State Examination (MMSE) score after treatment with donepezil, rivastigmine, or galantamine [8]. By 9 months, only 15.7% of patients responded to treatment, with two-thirds

2014 Clinical Correlations

174. Screening for cognitive impairment in older adults: a systematic review for the US Preventive Services Task Force

meaningful. Donepezil reduced scores by -2.03 (95% CI -2.68 to -1.38), galantamine by -2.25 (95% CI -2.94 to -1.55) and rivastigmine by -3.06 (95% CI -4.48 to -1.65). The 10 fair to good quality trials of memantine showed a pooled reduction in ADAS-cog score of -1.36 (95% CI -2.02 to -0.7). Several other interventions were considered including aspirin dietary supplements: none showed any significant benefit. AChEIs increased the risk of withdrawal due to adverse events (donepezil RR 1.79, 95% CI 1.50

Full Text available with Trip Pro

2013 DARE.

176. Cholinesterase inhibitors to reduce the symptoms of Alzheimer's disease

Cholinesterase inhibitors to reduce the symptoms of Alzheimer's disease This document prepares the clinician to discuss scientific data with the patient so they can make an informed decision together. Presenting cholinesterase inhibitors to patients What are cholinesterase inhibitors for? Cholinesterase inhibitors (ChEIs) are medications taken daily to modify the symptoms of Alzheimer’s disease. These medications (donepezil, rivastigmine and galantamine) inhibit the breakdown of acetylcholine (...) description and references: 1. Birks. Cochrane Database Syst Rev 2006, CD 005593(1). Study design: systematic review of 13, multi-centre, randomized, double- blind parallel group trials comparing individuals treated with ChEIs (donepezil, galantamine and rivastigmine) versus placebo. Participants: 7,298 individuals from Europe, North America and Australia (mean age 73; range 49-94) with mild to severe dementia due to Alzheimer’s disease. Length of treatment: Minimum of 6 months. 2. AD 2000 Collaborative

2014 Cancer Council Australia

177. Serotonergic and cholinergic modulation of functional brain connectivity: A comparison between young and older adults. (PubMed)

) and the acetylcholinesterase inhibitor galantamine (8 mg) was measured in 12 young and 17 older volunteers during a randomized, double blind, placebo-controlled, crossover study. A powerful dataset consisting of 522 RS-fMRI scans was obtained by acquiring multiple scans per subject before and after drug administration. Group × treatment interaction effects on voxelwise connectivity with ten functional networks were investigated (p < .05, FWE-corrected) using a non-parametric multivariate analysis technique (...) with cerebrospinal fluid, white matter, heart rate and baseline measurements as covariates. Both groups showed a decrease in sensorimotor network connectivity after citalopram administration. The comparable findings after citalopram intake are possibly due to relatively similar serotonergic systems in the young and older subjects. Galantamine altered connectivity between the occipital visual network and regions that are implicated in learning and memory in the young subjects. The lack of a cholinergic response

2018 NeuroImage

178. Reversal of mecamylamine-induced effects in healthy subjects by nicotine receptor agonists: Cognitive and (electro) physiological responses. (PubMed)

of the nicotinic antagonist mecamylamine on a battery of cognitive and neurophysiological test with coadministration of a placebo, nicotine or galantamine in order to reverse the cognitive impairment caused by mecamylamine.Thirty-three healthy subjects received a single oral dose of 30 mg of mecamylamine (or placebo) in combination with either 16 mg of oral galantamine or 21 mg of transdermal nicotine (or its double-dummy). Mecamylamine 30 mg induced significant disturbances of cognitive functions. Attention (...) and produced decrease in performance of tests evaluating motor coordination, sustained attention and short- and long-term memory. These effects could be partially reversed by the coadministration of nicotine, and to a lesser extent by galantamine.© 2018 The British Pharmacological Society.

2018 British journal of clinical pharmacology

179. An EEG nicotinic acetylcholine index to assess the efficacy of pro-cognitive compounds. (PubMed)

, we demonstrate reversal of mecamylamine-induced neurophysiological effects due to 16 mg of galantamine as well as administering 21 mg of nicotine transdermally.Our findings indicate that the mecamylamine challenge model jointly with the nAChR index-a measure of the nicotinic EEG profile-could aid future proof-of-pharmacology studies to demonstrate effects of nicotinic cholinergic compounds.This novel measure for quantifying nicotinic cholinergic effects on the EEG could serve as a useful tool

2018 Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology

180. In-Silico Characterization and in-Vivo Validation of Albiziasaponin-A, Iso-Orientin, and Salvadorin Using a Rat Model of Alzheimer's Disease (PubMed)

, and Salvadorin showed least binding energy and highest binding affinity among all the scrutinized compounds. Post-docking analyses showed the following free energy change for Albiziasaponin-A, Salvadorin, and Iso-Orientin (-9.8 to -15.0 kcal/mol) as compared to FDA approved drugs (donepezil, galantamine, and rivastigmine) for AD (-6.6 to -8.2 Kcal/mol) and interact with similar amino acid residues (Pro-266, Asp-344, Trp-563, Pro-568, Tyr-103, Tyr-155, Trp-317, and Tyr-372) with the target proteins

Full Text available with Trip Pro

2018 Frontiers in pharmacology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>